



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Chonglou Saponin VII

Item No. 39251

CAS Registry No.: 68124-04-9
Formal Name: (3 β ,25R)-17-hydroxyspirost-5-en-3-yl O-6-deoxy- α -L-mannopyranosyl-(1 \rightarrow 2)-O-[O-6-deoxy- α -L-mannopyranosyl-(1 \rightarrow 4)]- β -D-glucopyranoside

Synonyms: Paris Saponin VII, PS VII

MF: C₅₁H₈₂O₂₁

FW: 1,031.2


Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 4 years

Item Origin: Plant/*Paris polyphylla*



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Chonglou saponin VII is supplied as a solid. A stock solution may be made by dissolving the chonglou saponin VII in the solvent of choice, which should be purged with an inert gas. Chonglou saponin VII is soluble in methanol.

Description

Chonglou saponin VII is a steroid saponin that has been found in *P. polyphylla* and has anticancer activities.^{1,2} It inhibits the proliferation of HepG2 cells and HepG2 cells resistant to doxorubicin (HepG2/ADR cells) when used at concentrations of 1.98 and 2.97 μ M. Chonglou saponin VII (1.98 μ M) reduces ADR resistance in HepG2/ADR cells when administered in combination with ADR, an effect that is enhanced by the addition of the PI3K inhibitor LY294002 (Item No. 70920) and the p38 MAPK inhibitor SB203580. It also inhibits the proliferation of MDA-MB-231, MDA-MB-436, and MCF-7 breast cancer cells (IC₅₀s = 3.16, 3.45, and 2.86 μ M, respectively).² It induces apoptosis and autophagosome formation in the same cells. Chonglou saponin VII (1.5 mg/kg) induces intratumoral autophagy and reduces tumor growth in an MDA-MB-231 mouse xenograft model.²

References

1. Tang, G.-E., Niu, Y.-X., Li, Y., et al. Paris saponin VII enhanced the sensitivity of HepG2/ADR cells to ADR via modulation of PI3K/AKT/MAPK signaling pathway. *Kaohsiung J. Med. Sci.* **36**(2), 98-106 (2019).
2. Xiang, Y.-C., Peng, P., Liu, X.-W., et al. Paris saponin VII, a Hippo pathway activator, induces autophagy and exhibits therapeutic potential against human breast cancer cells. *Acta Pharmacol. Sin.* **43**(6), 1568-1580 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM